NO931697L - Lhrh-antagonister - Google Patents

Lhrh-antagonister

Info

Publication number
NO931697L
NO931697L NO93931697A NO931697A NO931697L NO 931697 L NO931697 L NO 931697L NO 93931697 A NO93931697 A NO 93931697A NO 931697 A NO931697 A NO 931697A NO 931697 L NO931697 L NO 931697L
Authority
NO
Norway
Prior art keywords
parent compound
dala10
leu7
ser4
pro9
Prior art date
Application number
NO93931697A
Other languages
English (en)
Other versions
NO931697D0 (no
Inventor
Shabo Tianjin Xiao
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of NO931697D0 publication Critical patent/NO931697D0/no
Publication of NO931697L publication Critical patent/NO931697L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

To antagonister er beskrevet: 1) fremgangsmåten for konstruksjon og syntese av LHRH-antagonister; 2) produkter oppnådd deretter ved anvendelse av ovennevnte fremgangsmåte. Med (NaC-daNal1, DpCIPhe2, D3Pal3, Ser4, Tyr5, DArg6, Leu7, Arg3, Pro9, Dala10)NE2 som foreldreforbindelse, en serie nye analoger uttrykt som (NAc-D2Xal1, ÅA2, ÅA3, Ser4, ÅA5, ÅA6, Leu7, ÅA3, Pro9, Dala10)NH2 blir oppnådd ved- finmodifikasjon av både lipofile områder og alkaliske områder av molekylet til foreldreforbindelsen. På denne måten kan den høye antiovulatorlske aktiviteten til foreldreforbindelsen bli opprettholdt og den histaminfrigjørende aktiviteten kan bli redusert til et nivå for å oppfølge det kliniske kravet.
NO93931697A 1990-11-10 1993-05-10 Lhrh-antagonister NO931697L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN90108955A CN1036343C (zh) 1990-11-10 1990-11-10 新促黄体生成素释放激素拮抗类似物的制备方法
PCT/EP1991/002110 WO1992008733A1 (en) 1990-11-10 1991-11-08 Lhrh-antagonists

Publications (2)

Publication Number Publication Date
NO931697D0 NO931697D0 (no) 1993-05-10
NO931697L true NO931697L (no) 1993-07-07

Family

ID=4881223

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931697A NO931697L (no) 1990-11-10 1993-05-10 Lhrh-antagonister

Country Status (29)

Country Link
EP (1) EP0564466B1 (no)
KR (1) KR100244624B1 (no)
CN (1) CN1036343C (no)
AT (1) ATE149520T1 (no)
AU (1) AU662496B2 (no)
CA (1) CA2095932C (no)
CZ (1) CZ284168B6 (no)
DE (1) DE69125024T2 (no)
DK (1) DK0564466T3 (no)
EE (1) EE03141B1 (no)
ES (1) ES2100965T3 (no)
FI (1) FI933156A7 (no)
GR (1) GR3023389T3 (no)
HR (1) HRP920585B1 (no)
IE (1) IE913915A1 (no)
LT (1) LT3971B (no)
LV (1) LV10106B (no)
NO (1) NO931697L (no)
NZ (1) NZ240505A (no)
PH (1) PH31178A (no)
PL (1) PL170564B1 (no)
PT (1) PT99458B (no)
RU (1) RU2123499C1 (no)
SI (1) SI9111779B (no)
SK (1) SK281319B6 (no)
UA (1) UA41300C2 (no)
WO (1) WO1992008733A1 (no)
YU (1) YU48831B (no)
ZA (1) ZA918847B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2136079A1 (en) * 1992-12-18 1994-07-07 Fortuna Haviv Lhrh antagonists having modified aminoacyl residues at positions 5 and 6
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
DE4338015A1 (de) * 1993-11-08 1995-05-11 Asta Medica Ag Verwendung von D-glucopyranuronsäuren und deren Derivaten zum Einbau in pharmakologisch wirksame Peptide und deren Salze
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
DE19544212A1 (de) * 1995-11-28 1997-06-05 Asta Medica Ag Neue LH-RH-Antagonisten mit verbesserter Wirkung
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
CN102675418B (zh) * 2011-03-15 2016-04-20 中国人民解放军军事医学科学院毒物药物研究所 Lhrh拮抗剂衍生物、其制备方法及用途
CN103524599B (zh) * 2012-07-05 2016-04-20 中国人民解放军军事医学科学院毒物药物研究所 环肽lhrh拮抗剂衍生物及其药物用途
CN104418936B (zh) * 2013-08-20 2018-06-05 中国人民解放军军事医学科学院毒物药物研究所 Lhrh拮抗剂衍生物及其药物用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4851385A (en) * 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity

Also Published As

Publication number Publication date
YU177991A (sh) 1994-06-24
NZ240505A (en) 1993-04-28
IE913915A1 (en) 1992-05-20
RU2123499C1 (ru) 1998-12-20
EP0564466A1 (en) 1993-10-13
HRP920585A2 (en) 1997-04-30
CA2095932C (en) 2003-02-25
PT99458A (pt) 1992-10-30
EE03141B1 (et) 1998-12-15
DE69125024T2 (de) 1997-07-17
CN1061605A (zh) 1992-06-03
FI933156A0 (fi) 1993-07-09
GR3023389T3 (en) 1997-08-29
ZA918847B (en) 1992-08-26
FI933156A7 (fi) 1993-07-09
WO1992008733A1 (en) 1992-05-29
LV10106B (en) 1995-04-20
DK0564466T3 (da) 1997-08-25
SK45393A3 (en) 1993-10-06
KR100244624B1 (ko) 2000-02-15
CN1036343C (zh) 1997-11-05
PL170564B1 (pl) 1996-12-31
NO931697D0 (no) 1993-05-10
YU48831B (sh) 2002-03-18
KR930703353A (ko) 1993-11-29
SI9111779A (en) 1997-04-30
SK281319B6 (sk) 2001-02-12
EP0564466B1 (en) 1997-03-05
LT3971B (en) 1996-05-27
HRP920585B1 (en) 2000-08-31
ES2100965T3 (es) 1997-07-01
SI9111779B (en) 2001-12-31
LTIP1513A (en) 1995-06-26
PL295427A1 (en) 1993-09-06
CA2095932A1 (en) 1992-05-11
CZ84893A3 (en) 1994-02-16
CZ284168B6 (cs) 1998-09-16
PH31178A (en) 1998-03-20
LV10106A (lv) 1994-05-10
PT99458B (pt) 1999-02-26
UA41300C2 (uk) 2001-09-17
ATE149520T1 (de) 1997-03-15
AU8861291A (en) 1992-06-11
AU662496B2 (en) 1995-09-07
DE69125024D1 (de) 1997-04-10

Similar Documents

Publication Publication Date Title
NO931697L (no) Lhrh-antagonister
CA2104873A1 (en) Compositions and Methods of Treatment of Sympathetically Maintained Pain
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
BG50924A3 (bg) Метод за получаване на фармацевтичен състав
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
LV10949A (lv) Aizvietoti 4-fenil-4piperidinkarboksamidi to iegusanas panemiens farmaceitiska kompozicija
DE69429186D1 (de) Liposomen, die materialien in partikelform enthalten
KR920700201A (ko) 신규 1α-히드록시비타민D 2 에피머 및 유도체
DE69128231D1 (de) Heterozyklische Alkylamine, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
DE69310602D1 (de) 3',5'-Ditertbutyl-4'-Hydroxyflavone, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzung mit Antioxidations- und Antivasokonstriktionsaktivität
EP0173664A3 (en) Biologically active benzimidazole compounds and process for their preparation
ATE104273T1 (de) Benzolsulfonamide und verfahren zu ihrer herstellung.
IL59603A (en) Peptides having ubiquitin-like activity,their preparation and pharmaceutical compositions containing them
HUT54113A (en) Process for producing butenecarboxylic acid derivatives and pharmaceutical compositions comprising such compounds
ES2128313T3 (es) Naftalimidas n-substituidas, su obtencion y empleo.
ATE26577T1 (de) 1-0-alkyl-3-amino-propan-1.2-diol-2-0phospholipide, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten.
ES8407039A1 (es) Un procedimiento para preparacion de una quinalozina.
KR900011757A (ko) 피리디늄 니트레이트, 그의 제조방법 및 용도
RU94017615A (ru) Способ получения пептида
KR900012884A (ko) (+)1-[(3,4,5-트리메톡시)-벤질옥시메틸]-1-페닐-N,N-디메틸-n-프로필아민, 그의 제조방법 및 치료학적 용도
ATE45357T1 (de) Theophyllin-7-essigsaurer ester von d,l-transsobrerol mit mucosecretolyt-fluidisierender und antibronchospastischer wirkung, ein verfahren zu seiner herstellung und pharmazeutische praeparate.
Caselli et al. Antihistaminic/antiallergic activity of 2-dialkylaminoalkylthio (OXY) 1-substituted benzimidazoles, evaluation “in vitro” and “in vivo”
JPS54100333A (en) Benzyl alcohol derivative and its preparation
RU92009228A (ru) Пептидный антагонист тиролиберина
TH5623A (th) สารผสมสำหรับความสะอาดพื้นผิวที่แข็ง

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application